Photocure ASA (PHCUF) Earnings Dates, Call Summary & Reports

Q: When does Photocure ASA (PHCUF) report earnings?

Photocure ASA (PHCUF) is schdueled to report earning on May 07, 2026, Before Open (Confirmed).

Q: What is Photocure ASA (PHCUF) earnings time?

Photocure ASA (PHCUF) earnings time is at May 07, 2026, Before Open (Confirmed).

Q: Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

Q: What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

Compare

9 Followers

Earnings Data

Report Date

May 07, 2026

Before Open (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

―

Last Year’s EPS

>-0.01

Same Quarter Last Year

Analyst Consensus

―

Based on 0 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Feb 18, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call conveyed clear commercial momentum with solid product revenue growth (9% Q4; 10% full-year ex-FX), meaningful unit gains (North America +13% units, rigid +19%), stronger commercial EBITDA and an improving installed base and account penetration (active accounts +22%). Strategic partnerships (Richard Wolf, ForTec, Claritas/ISC) and a healthy cash position support future growth and M&A ambitions. Offsetting these positives were timing-related revenue headwinds from the absence of 2024 milestones, a decline in operating cash flow, one-time COGS adjustments, FX headwinds, earn-out and buyback cash outflows, and uncertainty around regulatory approvals and CMS reimbursement timing. Overall, the positive operational and strategic developments significantly outweigh the near-term financial and timing challenges.

Company Guidance

Guidance: management reiterated 2026 topline guidance of 7–11% growth while expecting continued operating leverage (incremental revenue to flow disproportionately to commercial EBITDA), with North America growth “in the high teens” driven by rigid and mobile solutions and Europe in the mid-single digits (priority markets double‑digit); they highlighted catalysts including CMS reimbursement reform (decision target late summer, potential implementation 2027), FDA/CE pathways and OEM entries, and Flex market readiness targeted ~2027. Key metrics referenced to underpin the guidance: Q4 Hexvix/Cysview product revenue NOK 135m (+9% y/y cc) and full‑year product revenue NOK 530m (+10% y/y cc), total revenue NOK 532.6m, Q4 in‑market unit sales +13% North America / +4% Europe, Q4 rigid surgical unit growth +19%, active U.S. accounts +22% y/y to 384 (ForTec mobile in 134 accounts with >230 trained physicians), Flex <5% of U.S. business, full‑year commercial EBITDA excl. milestones/BD NOK 46.2m (Q4 commercial EBITDA NOK 8.4m ex‑BD/milestones; Q4 EBITDA excl. BD NOK 5.9m), cash NOK 238.9m, TAM estimates: >USD 1.3bn flexible cystoscopy and ~USD 2bn total BLC, and ongoing BD priorities (M&A focus in 2026, AI ENAiBLE study, Asieris milestones ~USD 18m received) to drive scale and margin expansion.

Product Revenue Growth (Hexvix/Cysview)

Q4 Hexvix/Cysview product revenue NOK 135 million, highest ever; Q4 product revenue +9% year-over-year in constant currency and full-year product revenue NOK 530 million (+10% YoY in constant currencies), at the top end of guidance.

North America Strong Performance

North America Q4 revenue +17% in constant currencies driven by 13% unit growth and ~4% price increases; North America rigid/mobile volumes up substantially with rigid surgical market unit growth +19% in Q4.

Expanding Account Base and Mobile Access (ForTec)

Active accounts increased ~22% year-over-year to 384; ForTec mobile solution reached 134 accounts with >230 trained physicians, underpinning access expansion and contributing materially to U.S. unit growth.

Europe Momentum and Equipment Upgrades

Europe Q4 revenue +4% and units +4%; Olympus Visera III rollout gaining traction with 60 installs through Q4, driving double-digit uplift in priority markets (DACH, Nordic, France, Italy, U.K.).

Improved Profitability and Operating Leverage

Commercial EBITDA (ex-BD and milestones) improved: Q4 NOK 5.9 million vs NOK 1.6 million in Q4 2024; full-year EBITDA (ex-BD/milestones) NOK 46.2 million vs NOK 24.0 million in 2024; 11 consecutive quarters of positive EBITDA and demonstrated operating leverage (commercial EBITDA margin up from 7% to 11% over 3 years).

Strong Balance Sheet

Year-end cash balance NOK 238.9 million and no term debt; equity NOK 484 million (68% of total assets), providing runway for growth and M&A focus in 2026.

Strategic Partnerships and Technology Initiatives

Partnerships progressing: Richard Wolf collaboration for flexible 4K BLC (on-track, interim flexible solution introduced in EU) and Claritas/Intelligent Scopes collaboration to develop BLC AI (ENAiBLE study initiated), adding a potential high-margin software component.

Asieris Milestones and China Progress

Photocure has received over USD 18 million in milestones from Asieris across Hexvix and Cevira programs; Hexvix has marketing authorization in China with commercial launch expected following device approval; Asieris's Chinese pivotal trial showed BLC detected additional lesions in 43.3% of patients using modern high-def equipment.

Photocure ASA (PHCUF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PHCUF Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 07, 2026	2026 (Q1)	- / -	-0.009	―	―	―
Feb 18, 2026	2025 (Q4)	-0.03 / -0.03	-0.023	-35.14% (>-0.01)
Oct 29, 2025	2025 (Q3)	>-0.01 / 0.02	-0.014	215.38% (+0.03)
Jul 30, 2025	2025 (Q2)	>-0.01 / <0.01	0.047	-84.51% (-0.04)
May 08, 2025	2025 (Q1)	>-0.01 / >-0.01	-0.031	69.07% (+0.02)
Feb 19, 2025	2024 (Q4)	0.02 / -0.02	0.048	-148.26% (-0.07)
Nov 13, 2024	2024 (Q3)	-0.03 / -0.01	-0.018	26.14% (<+0.01)
Aug 07, 2024	2024 (Q2)	0.03 / 0.05	0.017	182.50% (+0.03)
May 15, 2024	2024 (Q1)	-0.03 / -0.03	-0.045	32.33% (+0.01)
Feb 21, 2024	2023 (Q4)	-0.01 / 0.05	-0.098	149.46% (+0.15)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PHCUF Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 18, 2026	$6.51	$6.57	+0.92%
Oct 29, 2025	$5.37	$5.44	+1.30%
Jul 30, 2025	$5.94	$5.94	0.00%
May 08, 2025	$4.32	$4.32	0.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Photocure ASA (PHCUF) report earnings?

Photocure ASA (PHCUF) is schdueled to report earning on May 07, 2026, Before Open (Confirmed).

What is Photocure ASA (PHCUF) earnings time?

Photocure ASA (PHCUF) earnings time is at May 07, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PHCUF EPS forecast?

Currently, no data Available